タンパク質4含有ブロモドメイン治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Bromodomain Containing Protein 4 - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0882
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:143
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Bromodomain Containing Protein 4 – Pipeline Review, H1 2020
Summary

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 39 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 – Pipeline Review, H1 2020, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 17 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 4 molecules, respectively.

Report covers products from therapy areas Oncology, Dermatology, Infectious Disease, Immunology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Multiple Myeloma (Kahler Disease), Ovarian Cancer, Diffuse Large B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atopic Dermatitis (Atopic Eczema), Breast Cancer, Colorectal Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leukemia, Lung Cancer, Myelodysplastic Syndrome, Neuroblastoma, Non-Hodgkin Lymphoma, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Colon Cancer, Follicular Lymphoma, Hematological Tumor, Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Myeloproliferative Disorders, Pancreatic Cancer, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Adenocarcinoma, Advanced Malignancy, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Cognitive Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Fibrosis, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Idiopathic Pulmonary Fibrosis, Inflammation, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Liver Cancer, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Uveal Melanoma and Vascular Dementias.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Introduction
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Therapeutics Development
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Therapeutics Assessment
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Companies Involved in Therapeutics Development
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Drug Profiles
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Arvinas Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Discontinued Products, H1 2020

【掲載企業】

AbbVie Inc
Amgen Inc
Arvinas Inc
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
C4 Therapeutics Inc
Checkpoint Therapeutics Inc
Constellation Pharmaceuticals Inc
Epigene Therapeutics Inc
GlaxoSmithKline Plc
Kainos Medicine Inc
Ningbo Wenda Pharma
OHM Oncology
Oncopia Therapeutics LLC
Plexxikon Inc
Red Glead Discovery AB
Resverlogix Corp
SignalRx Pharmaceuticals Inc
Zenith Epigenetics Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[タンパク質4含有ブロモドメイン治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆